Clofazimine

FDA Drug Profile — Lamprene

Clofazimine is listed in the FDA National Drug Code directory with 3 NDC codes, marketed under brand name including Lamprene. Available dosage forms: powder, capsule, liquid filled.

Drug details

Generic Name
Clofazimine
Brand Names
Lamprene
Application Number
NDA019500
Sponsor
PROCOS SpA
NDC Codes
3
Dosage Forms
POWDER, CAPSULE, LIQUID FILLED
Routes
ORAL
Active Ingredients
CLOFAZIMINE

Indications and Usage

1 INDICATIONS AND USAGE LAMPRENE is an antimycobacterial indicated for the treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum. ( 1.1 ) To prevent the development of drug-resistance, LAMPRENE should be used only as a part of combination therapy for initial treatment of lepromatous leprosy. ( 1.2 ) 1.1 Lepromatous Leprosy LAMPRENE is indicated in combination with other anti-leprosy drugs for the treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy, and lepromatous leprosy complicated by erythema nodosum leprosum. 1.2 Usage To prevent the development of drug-resistance, LAMPRENE should be used only as a part of combination therapy for initial treatment of lepromatous (multibacillary) leprosy [see Dosage and Administration (2.1)] . For further guidance on the treatment of leprosy, contact the National Hansen’s Disease Clinical Center, Baton Rouge, Louisiana (LA) at (1-800-642-2477) or http://www.hrsa.gov/hansensdisease/clinicalcenter.html .

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.